Pacifica Partners Inc. Has $510,000 Stock Position in Eli Lilly and Company (NYSE:LLY)

Pacifica Partners Inc. lowered its stake in Eli Lilly and Company (NYSE:LLY) by 4.5% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 660 shares of the company’s stock after selling 31 shares during the period. Pacifica Partners Inc.’s holdings in Eli Lilly and Company were worth $510,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. Lipe & Dalton acquired a new position in shares of Eli Lilly and Company during the 4th quarter worth approximately $26,000. Core Wealth Advisors Inc. grew its position in shares of Eli Lilly and Company by 188.2% during the 4th quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock worth $29,000 after purchasing an additional 32 shares in the last quarter. Tidemark LLC acquired a new position in shares of Eli Lilly and Company during the 4th quarter worth approximately $29,000. Frank Rimerman Advisors LLC bought a new stake in shares of Eli Lilly and Company during the 4th quarter worth approximately $37,000. Finally, St. Johns Investment Management Company LLC lifted its holdings in shares of Eli Lilly and Company by 123.3% during the 4th quarter. St. Johns Investment Management Company LLC now owns 67 shares of the company’s stock worth $39,000 after acquiring an additional 37 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 194,978 shares of the firm’s stock in a transaction on Monday, June 17th. The shares were sold at an average price of $885.91, for a total value of $172,732,959.98. Following the completion of the sale, the insider now directly owns 97,583,810 shares in the company, valued at $86,450,473,117.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 194,978 shares of the firm’s stock in a transaction on Monday, June 17th. The shares were sold at an average price of $885.91, for a total value of $172,732,959.98. Following the completion of the sale, the insider now directly owns 97,583,810 shares in the company, valued at $86,450,473,117.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Donald A. Zakrowski sold 750 shares of the firm’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $819.47, for a total transaction of $614,602.50. Following the completion of the sale, the chief accounting officer now owns 7,130 shares of the company’s stock, valued at $5,842,821.10. The disclosure for this sale can be found here. Insiders sold a total of 772,475 shares of company stock worth $656,838,859 over the last three months. 0.13% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. Citigroup upped their price target on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a report on Tuesday, April 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $885.00 price target on shares of Eli Lilly and Company in a report on Monday. Finally, Argus upped their price target on shares of Eli Lilly and Company from $770.00 to $840.00 and gave the stock a “buy” rating in a report on Tuesday, May 14th. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $806.72.

Eli Lilly and Company Price Performance

LLY stock opened at $890.62 on Tuesday. Eli Lilly and Company has a 52-week low of $434.34 and a 52-week high of $905.45. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35. The company has a fifty day moving average price of $801.37 and a 200-day moving average price of $732.02. The company has a market capitalization of $846.45 billion, a P/E ratio of 131.17, a PEG ratio of 1.93 and a beta of 0.36.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, topping the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The company had revenue of $8.77 billion during the quarter, compared to analysts’ expectations of $8.94 billion. During the same period in the prior year, the company posted $1.62 earnings per share. Eli Lilly and Company’s revenue for the quarter was up 26.0% compared to the same quarter last year. As a group, equities analysts expect that Eli Lilly and Company will post 13.73 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, June 10th. Stockholders of record on Thursday, May 16th were given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 0.58%. The ex-dividend date of this dividend was Wednesday, May 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 76.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.